Eupraxia Pharmaceuticals (EPRX) Projected to Post Earnings on Monday

Eupraxia Pharmaceuticals (NASDAQ:EPRX) is anticipated to release its earnings data before the market opens on Monday, April 7th. Analysts expect Eupraxia Pharmaceuticals to post earnings of ($0.14) per share for the quarter.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its earnings results on Thursday, March 20th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). On average, analysts expect Eupraxia Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Eupraxia Pharmaceuticals Stock Down 1.5 %

Shares of Eupraxia Pharmaceuticals stock opened at $3.33 on Monday. Eupraxia Pharmaceuticals has a 12 month low of $2.20 and a 12 month high of $4.48. The stock has a market cap of $118.67 million and a PE ratio of -4.62. The business has a fifty day simple moving average of $3.53 and a 200-day simple moving average of $3.14.

Wall Street Analyst Weigh In

Separately, Craig Hallum initiated coverage on shares of Eupraxia Pharmaceuticals in a research report on Friday, February 21st. They issued a “buy” rating and a $12.00 price target for the company.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.